Geode Capital Management LLC Boosts Stock Position in Pro-Dex, Inc. (NASDAQ:PDEX)

Geode Capital Management LLC grew its stake in shares of Pro-Dex, Inc. (NASDAQ:PDEX) by 9.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,435 shares of the medical instruments supplier’s stock after buying an additional 2,296 shares during the period. Geode Capital Management LLC owned 0.84% of Pro-Dex worth $819,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Dimensional Fund Advisors LP lifted its position in shares of Pro-Dex by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock valued at $1,238,000 after buying an additional 3,067 shares in the last quarter. Bard Associates Inc. lifted its holdings in Pro-Dex by 17.6% in the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after purchasing an additional 2,031 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Pro-Dex by 7.9% in the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after purchasing an additional 900 shares in the last quarter. Finally, FMR LLC lifted its holdings in Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares in the last quarter. 15.28% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Pro-Dex

In related news, CFO Alisha Charlton sold 1,000 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $40.02, for a total transaction of $40,020.00. Following the completion of the transaction, the chief financial officer now owns 15,339 shares in the company, valued at $613,866.78. The trade was a 6.12 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 47.50% of the stock is owned by company insiders.

Pro-Dex Stock Performance

NASDAQ PDEX opened at $46.97 on Friday. The company has a market cap of $153.08 million, a P/E ratio of 30.50 and a beta of 0.56. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.94 and a current ratio of 3.41. The business’s 50 day moving average price is $47.92 and its 200-day moving average price is $31.93. Pro-Dex, Inc. has a fifty-two week low of $16.18 and a fifty-two week high of $59.60.

Wall Street Analyst Weigh In

A number of research firms recently commented on PDEX. Ascendiant Capital Markets boosted their price target on Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, November 11th. StockNews.com raised Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 14th.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.